Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2017
At a glance
- Drugs Forodesine (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Mundipharma International
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 19 Feb 2015 Status changed from recruiting to active, no longer recruiting a reported by ClinicalTrials.gov record.